Preview Access
Cosmetic Peat Association
ET
← All conditions

Eczema (Atopic Dermatitis)

Skin Conditions
ICD-10: L20 Prevalence: 10–20% of children, 1–3% of adults worldwide
Also known as: eczema, atopic dermatitis, AD, atopic eczema
skinscalp
Conventional treatment: Emollients, topical corticosteroids, calcineurin inhibitors, phototherapy, biologics (dupilumab)

Eczema (atopic dermatitis) is a chronic inflammatory skin condition characterized by dry, itchy, inflamed skin with impaired barrier function. It involves a combination of genetic predisposition, immune dysfunction (Th2 skewing), and environmental triggers.

Relevance to Peat Therapy

Peat addresses multiple pathological pathways in eczema simultaneously: anti-inflammatory effects reduce skin inflammation, moisturizing effects support the impaired skin barrier, anti-pruritic effects break the itch-scratch cycle, and antimicrobial effects address secondary infections common in eczematous skin. The pH compatibility of peat with skin’s acid mantle is particularly relevant for eczema patients, whose barrier is already compromised.

Evidence Landscape

Clinical evidence comes primarily from balneotherapy studies in Central European spa settings. Most studies report improvements in SCORAD (eczema severity scoring) after 2–3 week treatment courses. Evidence is moderate — predominantly cohort studies and clinical observations rather than large blinded RCTs. Some studies have difficulty separating peat-specific effects from the general benefits of spa therapy (stress reduction, climate, routine).

How Does Peat Help?

The biological mechanisms through which peat addresses this condition.

Treatment Options

Peat Balneotherapy Peat Compresses Peat Cream / Lotion

Evidence & Claims

treats balneotherapy (moderate)

Peat baths provide full-body anti-inflammatory and antiallergic immersion therapy

wollina-2009 — Review — humic substances adjuncts in topical therapy of inflammatory skin diseases including atopic dermatitis
zhernov-2020 — Topical peloid-derived HA suppressed DNCB-induced ACD in mice; broad cytokine suppression
treats face-masks (moderate)

FA inhibits mast cell degranulation and CCL17/CCL22 chemokines in atopic dermatitis

yamada-2007 — CP-FA inhibits β-hexosaminidase and histamine release from mast/basophilic cells
wu-2023 — FA attenuates AD by downregulating CCL17/CCL22 via p38 MAPK and JNK in keratinocytes
treats cream (moderate)

Leave-on peat cream provides sustained anti-inflammatory and barrier-support for daily AD management

verrillo-2022 — HA increases keratinocyte viability and decreases IL-6/IL-1β — protective and anti-inflammatory
wollina-2009 — Humic substances as adjuncts in topical therapy of AD
treats body-wraps (preliminary)

Peat body wraps for extensive eczema flares — moisturizing + anti-inflammatory

blonska-sikora-2024 — Review: peat moisturizing and anti-inflammatory properties in cosmetological context
treats compresses (preliminary)

Gentle peat compresses for sensitive or acutely inflamed eczematous skin

wollina-2009 — Peat applications for inflammatory skin conditions — gentler than full-strength paste
treats bath-additives (preliminary)

Home peat baths for maintenance between clinical treatments

gams-2020 — Peloid therapy for dermatological conditions including atopic dermatitis
wu-2023 — Topical FA attenuated DNCB-induced AD in mice: reduced ear thickness, erythema, serum CCL17/CCL22; inhibits p38 MAPK and JNK in keratinocytes; dose-dependent effect at 200-500 μg/mL